Trial Profile
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Epratuzumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Registrational
- Acronyms EMBODY4
- Sponsors UCB; UCB Pharma Inc
- 10 Feb 2019 This trial has been discontinued in UK(End-Date 2015-09-10).
- 14 Mar 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 02 Aug 2013 Planned End Date changed from 1 Feb 2016 to 1 Jan 2019 as reported by ClinicalTrials.gov.